Biopharma & Life Sciences
Recursion Pharmaceuticals Executive Compensation (FY25)
RXRX · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 18, 2026
177 figures on this page: 174 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Najat Khan: $9,194,805 → $5,349,065 (41.8% lower)
Say-on-pay support: 98.7% → 87.0% (11.7 points lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Recursion Pharmaceuticals' chief executive and what were they paid?
Najat Khan was paid $5,349,065 in total compensation as Chief Executive Officer and President for fiscal 2025. Compared with the $9,194,805 reported for fiscal 2024, Khan's total was 41.8% lower.
What was Recursion Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 87.0% of votes cast for or against in favor at the meeting held June 17, 2026.
Which companies are in Recursion Pharmaceuticals' peer group?
The disclosed peer group names AbCellera Biologics, Adaptive Biotechnologies, BridgeBio Pharma, C3.ai and Certara, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Christopher Gibson former Chief Executive Officer and President and current Chair of the Board | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Najat Khan Chief R&D and Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Christopher Gibson Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Ben Taylor Chief Financial Officer and President of Recursion UK | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Tina Marriott Executive Advisor and Former President and Chief Operating Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Secora Former Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
David Mauro Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Christopher Gibson Former Chief Executive Officer and President and current Chair of the Board Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Najat Khan Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Ben Taylor Chief Financial Officer and President of Recursion UK | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Ben Taylor | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Ben Taylor | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Christopher Gibson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Christopher Gibson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Najat Khan | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Najat Khan | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Najat Khan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Najat Khan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Najat Khan | Option | ◇ | — | ◇ | 2/3/2035 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/5/2035 | |
| Option | ◇ | — | ◇ | 8/1/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Christopher Gibson | Option | ◇ | — | ◇ | 2/9/2034 |
| Option | ◇ | — | ◇ | 2/3/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/1/2033 | |
| Option | ◇ | — | ◇ | 2/4/2032 | |
| Ben Taylor | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 12/19/2034 | |
| Option | ◇ | — | ◇ | 2/3/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Elaine Sun | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Robert Hershberg Lead independent director | ◇ | ◇ | ◇ | — | — | — | ◇ |
Zavain Dar | ◇ | ◇ | ◇ | — | — | — | ◇ |
Blake Borgeson | ◇ | ◇ | ◇ | — | — | — | ◇ |
Franziska Michor | ◇ | ◇ | ◇ | — | — | — | ◇ |
Dean Y. Li | ◇ | ◇ | ◇ | — | — | — | ◇ |
Christopher Gibson, Najat Khan, Zachary Bogue and Namandj Bumpus served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- AbCellera Biologics ABCL
- Adaptive Biotechnologies ADPT
- BridgeBio Pharma BBIO
- C3.ai AI
- Certara CERT
- Cytek Biosciences CTKB
- Denali Therapeutics DNLI
- Dyne Therapeutics DYN
- IDEAYA BioSciences IDYA
- Intapp INTA
- Relay Therapeutics RLAY
- Repligen RGEN
- Rocket Pharmaceuticals RCKT
- Schrodinger SDGR
- SoundHound AI SOUN
- Twist Bioscience TWST
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 17, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 18, 2025 | = | ◇ | ◇ | ◇ |
| 2022 | June 16, 2023 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Recursion Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Recursion Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
177 figures on this page: 174 cited to the filing that reported them, 3 calculated from figures it prints.
174 cited to the filing
3 calculated from the filing
Documents cited
- 0001601830-26-000080
- 0001601830-26-000065COMMUNICATION WITH OUR BOARD OF DIRECTORS · Director Compensation Table · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End Table · and 1 more section
- 0001601830-25-000088
- 0001601830-25-000062Summary Compensation Table for 2024, 2023 and 2022
- 0001601830-24-000040Summary Compensation Table for 2023, 2022 and 2021
- 0001601830-23-000048
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Recursion Pharmaceuticals executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/RXRX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Recursion Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Recursion Pharmaceuticals discloses
The companies named in RXRX's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}